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Functional assay for HER-2/neu demonstrates active signalling in a
minority of HER-2/neu-overexpressing invasive human breast tumours
MP DiGiovannal 2. D Carter', SD Flynn' and DF Stern'
Departments of'Pathology and 2Internal Medicine, Section ofMedical Oncology, Yale University School ofMedicine and Yale-New
Haven Hospital, 310 Cedar Street, New Haven, CT, 06510.
Summary Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis,
although its strength as a prognostic indicator varies widely in different reports. Variability may be due to
active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this
hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report,
we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast
carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating
overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological
characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-
2/neu as a prognostic indicator.
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HER-2/neu is overexpressed in 10-40% of human breast
carcinomas, and is reported to correlate with adverse
prognostic factors and to be an independent predictor of
poor prognosis itself (reviewed in Hynes and Stern, 1994).
However, the reported strength of such associations varies
widely among different studies, and some find minimal
prognostic ability of this marker. As a result, the utility of
HER-2/neu as a prognostic indicator remains a matter of
contention.
As level of expression is not absolutely indicative of
functional status, one potential cause of conflicting results
may be biological heterogeneity in the degree of signalling by
HER-2/neu among individual HER-2/neu-overexpressing
tumours. Like other receptor tyrosine kinases, signal
transduction by HER-2/neu proceeds via receptor autophos-
phorylation, recruitment of other signalling molecules and
substrate phosphorylation (reviewed in Hynes and Stern,
1994). Although signalling activity of overexpressed receptors
increases in graded fashion as receptor abundance increases,
the signalling activity even of overexpressed receptors is
dramatically affected by ligand binding. Moreover, activation
of receptors leads to down-regulation, resulting in a lower
steady-state abundance. Thus, overall levels do not reflect the
degree to which the receptor is signalling and by extension
the extent to which it influences the behavior of the tumour.
To address this issue, we have developed a monoclonal
anti-HER-2/neu antibody, designated PN2A, which has
absolute specificity for the phosphorylated form of the
receptor (DiGiovanna and Stern, 1995). As autophosphoryla-
tion is a hallmark of active signalling, PN2A is uniquely
suitable for specifically detecting activated receptor. We have
previously reported that among five cases of ductal
carcinoma in situ (DCIS) with HER-2/neu overexpression,
PN2A detected phosphorylated receptor in only two
(DiGiovanna and Stern, 1995), in support of our hypoth-
esis. In this work, we extend our observations by applying
this functional assay to a large series of invasive breast
tumours, and we describe the frequencies of such occurrences
as well as their clinicopathological characteristics.
Materials and methods
Selection of cases
A total of 262 cases of invasive or mixed invasive and in situ
breast carcinomas ascertained between 1992 and 1994 at
Yale-New Haven Hospital (New Haven, CT, USA) were
randomly selected from the archival tissue bank of the
Department of Pathology. All blocks were paraffin sections
that had been fixed in 10% neutral buffered formalin. The
presence of invasive carcinoma was verified in haematoxylin
and eosin (H&E) sections of each case by a surgical
pathologist (DC). Nineteen blocks were found to have only
in situ carcinoma (CIS) remaining, and another 20 blocks had
no carcinoma at all remaining. These 39 cases were
eliminated from data tabulation, leaving 223 cases for
analysis.
Immunohistochemistry
Immunohistochemical staining for HER-2/neu was performed
essentially as described previously (DiGiovanna and Stern,
1995). The phosphorylation-insensitive anti-HER-2/neu anti-
body Ab3 (clone 3B5, Oncogene Science, Manhasset, NY,
USA) was used exactly as described (DiGiovanna and Stern,
1995). Phosphorylation state-dependent anti-HER-2/neu
monoclonal antibody PN2A was affinity purified and used
at a concentration of 20 ig ml-'. Antigen retrieval by the
pressure cooking method (Norton et al., 1994) was also used
to enhance PN2A immunostaining. For both antibodies, only
a membranous pattern of immunostaining was considered
positive (see DiGiovanna and Stern, 1995 for a discussion of
interpretation of staining patterns). The antigen retrieval
method caused an increase in diffuse cytoplasmic staining
with PN2A compared with staining in the absence of this
step. We consider this cytoplasmic staining artefactual
background, as it is generally not observed with the Ab3
staining and it is also seen in HER-2/neu-negative (i.e. Ab3-
negative) tumours. It is not expected that phosphorylated
receptor (PN2A staining) would be detectable in the absence
of any detectable receptor expression (Ab3 staining). As
expected, the first 20 Ab3-negative cases that were stained
with PN2A were all found to be negative for PN2A
membrane staining. For the remainder of the study, PN2A
staining was performed only on Ab3-positive tumours. Each
sample was scored semiquantitatively as to the intensity of
the membranous staining on a four-point scale, with 0
Correspondence: DF Stern, Yale University School of Medicine,
Department of Pathology, BML 342, 310 Cedar Street, New Haven,
CT06510 USA
Received 3 November 1995; revised 22 February 1996; accepted 7
March 1996Signalling by HER-2/neu in invasive breast tumours
MP DiGiovanna et al i
803
a
P" --[
.0w--;--~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.............X^.
Figure I Immunohistochemical staining ofbreast carcinomas with anti-HER-2/neu antibodies Ab3 (left) and PN2A (right). Case 1,
(a and b) Pure invasive ductal carcinoma positive for both Ab3 (a) and PN2A (b). Case 2, (c and d) Pure invasive ductal carcinoma
positive for Ab3 (c) but negative for PN2A (d). [In (d) a diffuse light non-specific background was exaggerated by the filter used for
black and white photography, although under direct microscopy the cellular details were clearer.] Case 3 (e-h) harbours invasive
carcinoma positive for Ab3 (e) and PN2A (f), and CIS positive for Ab3 (g) and PN2A (h). Case 4 (i-1) harbours invasive carcinoma
positive for Ab3 (i) but negative for PN2A (j), while it harbours CIS positive for both Ab3 (k) and PN2A (1). Original
magnification x 100.Signalling by HER-2/neu in invasive breast tumours
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indicating absence of membrane staining, 1+ the least
amount of staining detectable and 4+ representing the most
intensely staining specimens. A tumour known to express
phosphorylated HER-2/neu was run as a positive control
with each batch.
Oestrogen receptor (ER) and progesterone receptor (PR)
levels were assayed immunohistochemically at the time of
surgical resection. The assay was performed by the Yale-
New Haven Hospital clinical pathology laboratory using the
respective antibodies and staining kits from Abbott Labs
(North Chicago, IL, USA). Paraffin sections stained for ER
were pretreated with pronase.
Flow cytometric analysis
To determine the per cent S-phase and ploidy in formalin-
fixed, paraffin-embedded tissue, the nuclear DNA content
was analysed as described previously (Filderman et al., 1992).
Results
A total of 223 randomly selected cases of invasive (or mixed
invasive and CIS) human breast tumours were examined for
overexpression of HER-2/neu by immunohistochemical
staining of formalin-fixed, paraffin-embedded archival speci-
mens. Membranous immunostaining with Ab3 indicative of
HER-2/neu overexpression was detected in the invasive
component in 20 cases, or 9% overall (Figure 1). The
percentage of positively staining cases was roughly equivalent
for all pathological categories, with the exception of negative
staining for all (11) cases having lobular carcinoma as the
only invasive component. For cases with an original
diagnosis of invasive ductal carcinoma plus any CIS, both
components were remaining in 74 of the blocks examined. Of
these 74 blocks, the invasive and CIS components were
concordant for HER-2/neu overexpression in all but six cases.
There were three cases in which the CIS stained but the
invasive component did not, and three cases in which the
invasive component stained but the CIS did not.
Each of the 20 HER-2/neu-overexpressing cases was
evaluated for activation of HER-2/neu by PN2A immuno-
histochemistry, and seven (35%) were found to be positive
(Figure la and b compared with c and d). Two of the seven
PN2A-positive cases also harboured HER-2/neu-overexpress-
ing CIS, and the CIS was also PN2A positive (one case
shown in Figure le-h). Of the 13 cases in which the invasive
carcinoma was PN2A negative, three harboured HER-2/neu-
overexpressing CIS, and two of these CIS components were
PN2A positive (one case shown in Figure li-1). Although the
numbers are small, these data suggest that when the CIS is
not phosphorylated, the invasive component will also not be
phosphorylated, but when the CIS is phosphorylated, the
invasive component may or may not be. Thus, if there is a
progression from CIS to invasive carcinoma, it appears that
non-phosphorylated CIS remains non-phosphorylated upon
invasion, but phosphorylated CIS gives rise to invasive
carcinoma, which may remain phosphorylated or become
unphosphorylated. Mechanistically, there may be increased
phosphatase activity upon invasion or decreased ligand
abundance in the microenvironment of the stroma. The
inability to maintain activation upon invasion could remove
the selective pressure for HER-2/neu overexpression, poten-
tially explaining the well-described lower frequency of
overexpression in invasive compared with pure in situ
carcinoma. Most importantly, it is clear that HER-2/neu
phosphorylation, a reflection of activation, occurs in only a
subset of the invasive breast tumours that overexpress this
receptor.
Consistent with other studies, overexpression of HER-2/
neu showed a trend towards inverse association with ER
(Table I), with a 45% rate of ER positivity among 'neu+'
cases (9/20) vs a 59% rate of ER positivity among 'neu-'
cases (120/203). Phosphorylated HER-2/neu (Pneu) was
associated with a similar rate of ER positivity as was overall
HER-2/neu. More strikingly, a statistically significant inverse
association was found between HER-2/neu and PR (Table I),
with a 20% rate of PR positivity among 'neu +' cases (4/20)
vs a 52% rate ofPR positivity among 'neu-' cases (105/201).
In addition, in the case of PR, phosphorylated HER-2/neu
demonstrated an even more dramatic inverse association,
with PR present in 31% (4/13) of 'neu+/Pneu-' cases vs 0%
(0/7) of 'neu+/Pneu+' cases. Thus, while HER-2/neu
overexpression is inversely associated with hormone receptor
Table I Clinicopathological characteristics stratified by invasive component staining for overall HER-2/neu,
phosphorylated HER-2/neu (Neu+/Pneu+) and non-phosphorylated HER-2/neu (Neu +/Pneu-).
Category
ER+
PR+
LN+
Nuclear grade
1
2
3
Histological grade
1
2
3
Ploidy
Diploid
Tetraploid
Aneuploidd
S-Phase
Low
High
Age (years)
<50
>50
Neu- (%)
120/203 (59)
105/201 (52)
49/143 (34)
5/174 (3)b
128/174 (74)
42/174 (24)
10/174 (6)C
85/174 (49)
81/174 (47)
66/158 (42)
27/158 (17)
65/158 (41)
83/113 (73)
30/113 (27)
60/203 (30)
143/203 (70)
Neu+ (%) Neu +/Pneu- (%) Neu +/Pneu + (%)
9/20 (45)
4/20 (20)'
6/13 (46)
0/19 (0)
10/19 (53)
9/19 (47)
1/19 (5)b
6/19 (32)
13/19 (68)
3/10 (30)
3/10 (30)
4/10 (40)
4/6 (67)
2/6 (33)
8/20 (40)
12/20 (60)
6/13 (46)
4/13 (31)
4/9 (44)
0/12 (0)
7/12 (58)
5/12 (42)
1/12 (8)b
4/12 (33)
8/12 (67)
3/7 (43)
2/7 (29)
2/7 (29)
4/5 (80)
1/5 (20)
6/13 (46)
7/13 (54)
3/7 (43)
0/7 (0)'
2/4 (50)
0/7 (0)
3/7 (43)
4/7 (57)
0/7 (0)
2/7 (29)
5/7 (71)
0/3 (0)
1/3 (33)
2/3 (67)
0/1
1/1
2/7 (29)
5/7 (71)
aStatistically significant differences from 'Neu-' results by Chi-square test at P<0.01. bOne case had two
components ofdiffering grades. 'Two cases had two components ofdiffering grades. dOther than tetraploid.
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expression, it appears that activated, phosphorylated HER-2/
neu correlates with absence of PR strikingly more strongly
than does overall HER-2/neu.
As reported by others, we found that all 'neu+' cases
showed trends towards higher nuclear grades, higher
histological grades and lymph node positivity (Table I).
Stratification by phosphorylation status using PN2A was
notable for a trend towards higher nuclear grade when
receptor is phosphorylated. HER-2/neu-overexpressing tu-
mours also showed a tendency towards higher frequency of
aneuploidy (Table I). For the three 'neu +/Pneu +' cases for
which ploidy data were available, all three were aneuploid,
whereas the 'neu +/Pneu-' cases showed a similar frequency
of aneuploidy as the 'neu-' cases (Table I). No distinct
trends were obvious for S-phase fraction analysis or age
stratification.
One potential technical consideration of our studies is that
PN2A staining may simply reflect the subpopulation of
tumours with the highest levels of HER-2/neu overexpression.
If all HER-2/neu were actually phosphorylated, but PN2A
had significantly less sensitivity than Ab3 in detecting antigen
under optimal conditions, then PN2A could simply identify
the tumours with the highest levels of HER-2/neu over-
expression. In that scenario, PN2A staining would be closely
correlated with Ab3 staining. However, the overall level of
receptor expression (Ab3 staining) by necessity defines the
limits of detection of receptor phosphorylation (PN2A
staining). It is also true that cell culture experiments have
shown that the greater the level of HER-2/neu overexpres-
sion, the higher the basal level of receptor phosphorylation
(Stern et al., 1988). Therefore, even if the phosphorylation of
HER-2/neu was completely random, a certain degree of
association between Ab3 and PN2A would be necessary. We
addressed this issue by examining semiquantitatively the
intensity of PN2A staining for phosphorylated HER-2/neu in
comparison with Ab3 staining for overall HER-2/neu on a
four-point scale as described in Materials and methods. As
shown in Figure 2, there is some variation between the two
variables. Although there is a tendency for the strongest
overexpressors to have detectable phosphorylation, consistent
with cell culture experiments, there are examples of cases with
low Ab3 HER-2/neu staining (1+ and 2+) that still have
detectable PN2A staining, as well as cases with very strong
HER-2/neu staining (3 + and 4+) that have undetectable
PN2A staining. The Pearson's coefficient of correlation
r =0.339, again demonstrating a weak correlation. Hence,
PN2A positivity does not simply select for the highest
overexpressing cases. Therefore, we conclude that PN2A
detects HER-2/neu that has been specifically activated, either
by agonistic ligand, transmodulating factors or by activating
mutation (although the latter has not been reported in human
breast carcinoma; Lemoine et al., 1990).
Discussion
In this report, we demonstrate that in invasive breast
carcinoma HER-2/neu may exist either in a phosphorylated,
and therefore actively signalling, state or in a non-
phosphorylated and presumably inactive state. Tumours
exprest ing activated HER-2/neu are strikingly PR negative,
as well as possibly having a tendency towards higher nuclear
grade and aneuploidy, although a larger series of HER-2/neu-
overexpressing tumours will be required to verify these
findings. These results confirm and refine additional previous
results from our laboratory employing image analysis using
antiphosphoreceptor polyclonal antibody Al, which recog-
nizes both phosphorylated HER-2/neu and epidermal growth
4+
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z
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2+
1+
0+
1+ 2+ 3+ 4+
Ab3
Figure 2 Scatter plot of intensity of immunohistochemical
staining with PN2A as compared with Ab3. Pearson's coefficient
of correlation r=0.339.
factor receptor (Bacus et al., 1996). In that study, which was
performed on frozen sections non-randomly selected such that
most overexpressed HER-2/neu, we also found a moderate
correlation between staining for HER-2/neu and phosphory-
lated receptors, and we found HER-2/neu and phosphorylated
receptor scores to correlate inversely with PR.
In the present study, the overall frequency of HER-2/neu
overexpression (9%) is in the lower range of what has
generally been reported in the literature for invasive
carcinomas (often up to 20%). One potential reason is that
the Ab3 antibody may have a lower sensitivity than
antibodies used in other studies. In a comparison of
sensitivities of a large panel of antibodies to HER-2/neu by
Press et al. (1994), Ab3 (clone 3B5) had 61% the sensitivity
of the most sensitive antibody and an estimated 50%
sensitivity compared with the 'ideal result' (it also had a
98% specificity). We chose this antibody because it was
prepared against a peptide of the same amino acid sequence
as PN2A. Thus, staining with Ab3 assured that the PN2A
epitope was intact.
In summary, we have demonstrated that HER-2/neu is
phosphorylated, and therefore actively signalling, in a
minority of the invasive breast carcinomas overexpressing
this receptor. As a non-functioning receptor is unlikely to
influence the phenotype of a tumour regardless of its level of
expression, we predict that tumours harbouring activated
HER-2/neu probably have a significantly more aggressive
clinical course, and that those harbouring inactive receptors
probably do not differ from those lacking receptor over-
expression. A retrospective analysis of a large series of breast
tumours with long-term follow-up using this novel functional
assay is under way in our laboratory to test this prediction.
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